Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Accurate Diagnosis of dMMR/MSI-H Status Is Key for Nivolumab/Ipilimumab Treatment in mCRC

October 16th 2024

Thierry André, MD, discusses findings from subgroup analyses of the CheckMate 8HW trial of nivolumab/ipilimumab in dMMR/MSI-H metastatic colorectal cancer.

FDA Approves Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy

October 15th 2024

The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.

FDA Grants Orphan Drug Designation to IMM-1-104 for Pancreatic Cancer

October 15th 2024

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

FDA Grants Fast Track Designation to LP-184 for Glioblastoma

October 15th 2024

LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.

Toripalimab Wins Approval in India and Hong Kong for Recurrent/Metastatic Nasopharyngeal Carcinoma

October 15th 2024

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.

Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC

October 15th 2024

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

Increased ctDNA and MMR Testing May Alter Adjuvant and Neoadjuvant CRC Management

October 15th 2024

Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

October 15th 2024

Chad Tang, MD, discusses how radiation could play a role in advanced renal cell carcinoma.

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

October 14th 2024

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

October 14th 2024

NKT2152, a novel HIF2α inhibitor, produced responses in heavily pretreated advanced clear cell renal cell carcinoma.

BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL

October 14th 2024

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia.

Empowering Breast Surgeons: A Call for Collective Action

October 14th 2024

As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC

October 13th 2024

The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.

FDA Grants Orphan Drug Designation to LMP744 for Glioma

October 11th 2024

LMP744 has been granted orphan drug designation by the FDA for the treatment of patients with glioma.

FDA Approves Inavolisib Plus Palbociclib/Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer

October 10th 2024

The FDA approved inavolisib plus palbociclib/fulvestrant for select PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

October 10th 2024

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

October 10th 2024

Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.

Talazoparib Plus Enzalutamide Improves OS in mCRPC

October 10th 2024

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

October 10th 2024

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.